World Journal of
Clinical Oncology

World J Clin Oncol 2017 April 10; 8(2): 96-177
<table>
<thead>
<tr>
<th>Page</th>
<th>Section</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>96</td>
<td>EDITORIAL</td>
<td>Watch and wait policy in advanced neuroendocrine tumors: What does it mean?</td>
<td>Fazio N</td>
</tr>
<tr>
<td>106</td>
<td>FRONTIER</td>
<td>Leptin signaling and cancer chemoresistance: Perspectives</td>
<td>Candelaria PV, Rampoldi A, Harbuzariu A, Gonzalez-Perez RR</td>
</tr>
<tr>
<td>120</td>
<td>REVIEW</td>
<td>Targeted therapies in breast cancer: New challenges to fight against resistance</td>
<td>Masoud V, Pagès G</td>
</tr>
<tr>
<td>135</td>
<td>MINIREVIEWS</td>
<td>How best to manage gastrointestinal stromal tumor</td>
<td>Lanke G, Lee JH</td>
</tr>
<tr>
<td>145</td>
<td></td>
<td>Immunotherapies in sarcoma: Updates and future perspectives</td>
<td>Ghosn M, El Rassy E, Kourie HR</td>
</tr>
</tbody>
</table>
World Journal of Clinical Oncology
Volume 8 Number 2 April 10, 2017

ABOUT COVER
Editorial Board Member of World Journal of Clinical Oncology, Hua-Feng Wei, MD, PhD, Research Associate, Cancer Center Lab, General Hospital of Chinese PLA, China and Second Military Medical University, International Joint Cancer Institute, Beijing 100853, China

AIM AND SCOPE
World Journal of Clinical Oncology (World J Clin Oncol, WJCO, online ISSN 2218-4333, DOI: 10.5306) is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

IFJCO covers a variety of clinical medical topics, including etiology, epidemiology, evidence-based medicine, informatics, diagnostic imaging, endoscopy, tumor recurrence and metastasis, tumor stem cells, radiotherapy, chemotherapy, interventional radiology, palliative therapy, clinical chemotherapy, biological therapy, minimally invasive therapy, physiotherapy, psycho-oncology, comprehensive therapy, and oncology-related nursing. Priority publication will be given to articles concerning diagnosis and treatment of oncology diseases. The following aspects are covered: Clinical diagnosis, laboratory diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional treatment, minimally invasive therapy, and robot-assisted therapy.

We encourage authors to submit their manuscripts to WJCO. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great clinical significance.

INDEXING/ABSTRACTING
World Journal of Clinical Oncology is now indexed in PubMed, PubMed Central and Scopus.

FLYLEAF
I-III

EDITORIAL BOARD

NAME OF JOURNAL
World Journal of Clinical Oncology

ISSN
ISSN 2218-4333 (online)

LAUNCH DATE
November 10, 2010

FREQUENCY
Bimonthly

EDITOR-IN-CHIEF
Godefridus J Peters, PhD, Professor, Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam 1081 HV, Netherlands

EDITORIAL BOARD MEMBERS
All editorial board members resources online at http://www.wjgnet.com/2218-4333/editorialboard.htm

EDITORIAL OFFICE
Xiu-Xiu Song, Director

PUBLISHER
Baishideng Publishing Group Inc
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: editorialoffice@wjgnet.com
Help Desk: http://www.f6publishing.com/helpdesk
http://www.wjgnet.com

PUBLICATION DATE
April 10, 2017

COPYRIGHT
© 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non-commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT
All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS
http://www.wjgnet.com/bpg/getinfo/204

ONLINE SUBMISSION
http://www.f6publishing.com
Study of recombinant human interleukin-12 for treatment of complications after radiotherapy for tumor patients

Na Guo, Wen-Qin Wang, Xiao-Jing Gong, Lei Gao, Li-Rong Yang, Wei-Na Yu, Hong-Yu Shen, Ling-Qin Wan, Xi-Feng Jia, Yi-Shan Wang, Yi Zhao

Na Guo, Xiao-Jing Gong, Lei Gao, Li-Rong Yang, Wei-Na Yu, Hong-Yu Shen, Ling-Qin Wan, Xi-Feng Jia, Yi-Shan Wang, Yi Zhao

Center for Tumor Treatment, People’s Liberation Army 107th Hospital, Yantai 264002, Shandong Province, China

Wen-Qin Wang, Academy of Military Medical Sciences, Sanatorium for Retired Cadres, Beijing 100039, China

Yi Zhao, Kang Litai Pharmaceutical Co. Ltd., Qingdao 266001, Shandong Province, China

Author contributions: Wang YS and Zhao Y contributed to the conception of the study; Guo N and Wang WQ contributed significantly to analysis and manuscript preparation; Guo N, Gao L and Shen HY performed the data analyses and wrote the manuscript; Wang WQ and Gong XJ helped perform the analysis with constructive discussions; Yang LR and Yu WN collected specimens and detected indexes; all the authors contributed to this article.

Institutional review board statement: This study was reviewed and approved by the scientific ethical committee of the Hospital. All operations were performed according to international guidelines concerning the care and treatment of cancer patients.

Informed consent statement: Patients were informed of the purpose of the experiment and agreed to treatment with rhuIL-12. Informed consent was obtained in all cases, and protocols were approved by the scientific ethical committee of the Hospital.

Conflict-of-interest statement: The authors declare no conflicts of interest.

Data sharing statement: No additional unpublished data are available.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Invited manuscript

Correspondence to: Dr. Yi-Shan Wang, Center for Tumor Treatment, People’s Liberation Army 107th Hospital, 7 Zhichu South Road, Yantai 264002, Shandong Province, China. wangyishan288@163.com
Telephone: +86-535-2933528
Fax: +86-535-2933500

Received: October 11, 2016
Peer-review started: October 14, 2016
First decision: November 14, 2016
Revised: December 14, 2016
Accepted: January 2, 2017
Article in press: January 4, 2017
Published online: April 10, 2017

Abstract

AIM
To evaluate the treatment effects of recombinant human interleukin-12 (rhIL-12) on radiotherapy complications, such as severe myelosuppression or pancytopenia, the decline or imbalance of immune function, etc.

METHODS
The patients received high-dose and short-course precise radiotherapy, such as Cyber knife and image-guided radiotherapy (IGRT), which can cause myelosuppression or pancytopenia and immune function decline within a short time. One-hundred subjects were enrolled in the study, and 50 were randomized to a treatment group which used rhIL-12 and 50 were randomized to a control group which used symptomatic and supportive therapy after radiotherapy. The 50 subjects in the treatment group were further divided into five subgroups and intervened...
with rhIL-12 at a dose of 50, 100, 150, 200 or 250 ng/kg respectively. The dose-effect relationship was observed.

RESULTS
RhIL-12 significantly attenuated the decrease of peripheral blood cells in the treatment group, and immune function was improved after treatment. Due to the different radiation doses, there was a fluctuation within 12 h after treatment but mostly showing an increasing trend. As to the clinical manifestations, 2 patients in the 250 ng/kg subgroup showed low fever after administration, 1 patient in the 200 ng/kg subgroup and 2 patients in the 250 ng/kg subgroup showed mild impairment of liver function during the observation period.

CONCLUSION
RhIL-12 has effective therapeutic and protective effects on complications following radiotherapy, such as the decline of blood cells, myelosuppression and the decline or imbalance of immune function, which indicated good prospects for development and application.

Key words: Recombinant human interleukin-12; Cancer prevention; Radiotherapy complications; Clinical research

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Recombinant human interleukin-12 (rhIL-12) is a new kind of biological agent secreted by Chinese hamster ovary cells. Study has shown that it has the advantage of promoting recovery of hematopoietic function, regulating the body's immunity and inhibiting angiogenesis growth. At present, the research of rhIL-12 stays in the foundational realm and in animal experimentation. In our study, however, there were 100 patients with large or numerous tumors (more than two) and who received precision radiotherapy (Cyber knife or image-guided radiotherapy). The results showed that rhIL-12 can prevent radiation damage, improve hematopoietic function, regulate immunity, reduce the side effect of radiotherapy and improve the quality of life of patients.


MATERIALS AND METHODS

Objectives
To observe 100 patients with mid-advanced tumors who were treated with Cyber knife or image-guided radiotherapy (IGRT) in the People's Liberation Army 107th Hospital, from October 2014 to June 2016. Inclusion criteria were: (1) Tumor confirmed by pathology, CT or MRI diagnosis, for which the clinical staging criteria were III–IV according to the World Health Organization (WHO); (2) ECOG score of 1 to 4 points; (3) Postoperative recurrence or lymphocytes invasion and metastasis, and need for radiosurgery; and (4) Provision of written informed consent for research and therapy. Exclusion criteria were: (1) Illness combined with tuberculosis or serious failure of important organs, such as heart, liver, kidney, lung, etc.; (2) Presence of benign tumors; (3) History of organ transplantation or allergies; and (4) Pregnant or lactating women or women of childbearing age. The experimental study was approved by the hospital's ethics committee.

In the treatment group, 34 of the subjects (68%) were...
males and 16 (32%) were females; the mean age was 58.5-year-old (range: 27-83 years). Fifty subjects (30%) had lung cancers, 12 (24%) had liver cancers, 8 (16%) had head tumors, 1 (2%) had pancreatic cancer and 14 (28%) had other tumors. Solid relapse and metastasis tumor, for which size of the nidus could be assessed, accounted for 98% (n = 49) of the cases. Diffuse invasive metastatic tumor accounted for 2% (n = 1) of the cases, and the tumor diameter ranged from 3 cm to 16 cm. The patients who were classified as recurrent after the surgery or with more than 2 lesions accounted for 96% (n = 48) of the cases. In the control group, 28 of the subjects (56%) were males and 22 (44%) were females; the mean age was 57.4-year-old (range: 25-79 years). Twenty subjects (40%) had lung cancers, 15 (30%) had liver cancers and 15 (30%) had pancreatic cancers.

**Main equipment, drugs and reagents**

**Equipment:** Cyber knife, third-generation model produced by a United States’ accuracy company; IGRT, Eiekta Synergy model produced by a Swedish medical company; Flow cytometer produced by the United States’ BD Biosciences; Enzyme-mark instrument produced by a United States’ automation company; Chemiluminescence apparatus and automatic biochemistry analyzer produced by Roche Company; Hematology analyzer produced in Japan.

**Drugs and reagents:** RhIL-12 (for injection) produced by Qingdao Litai Kang Pharmaceutical Co. Ltd. Antibodies used in the study were purchased from BD Biosciences, including anti-human-IgG-FITC, anti-human-CD45-FITC, anti-human-CD56-PE and anti-human-CD3-PerCP-CD4-FITC-CD8-PE. Hemolysin was produced by an American research and development company.

**Methods:** After being admitted to hospital, all patients’ data were recorded for the three routine (liver and kidney function, heart function, bleeding and clotting time) and the imaging examination (such as electrolytes, color Doppler, CT and IMT), as well as adverse reactions, etc. All patients signed “consent form of precise radiotherapy”; “consent form of experimental study” and “agreement about the clinical application of rhIL-12 for prevention and treatment of malignant tumor radiotherapy complications”.

According to the research program, the patients were divided into 50, 100, 150, 200 and 250 ng/kg different-dose subgroups, and injected with rhIL-12 subcutaneously. Peripheral blood samples (for red blood cell (RBC), white blood cell (WBC) and platelet (PLT) assessment) and the immunophenotypes (CD4/8, CD45 and CD56) were collected before dosing (0 d) and at 12 h, 3 d, 7 d, 10 d, 14 d, 21 d, 28 d after dosing respectively. The effects on hematopoietic function and immune function were observed, as well as the dose-effect relationship. The control group used symptomatic supportive treatment.

**Efficacy evaluation criteria**

**Test evaluation:** The patients who accepted high-dose and short-course of accurate radiotherapy, such as cyber knife and IGRT, could experience induction of decrease of peripheral blood cells and decline or imbalance of immune function. In this study, rhIL-12 was given to explore the interventional effects on radiation oncology surgery patients, including effects on hematopoietic function and immune function as well as dose-effect relationship and to provide scientific basis for drug development and clinical application.

**WHO objective evaluation criteria:** Complete remission (CR) indicated all symptoms and signs disappearing for 4 wk; partial remission (PR) indicated the tumor size was estimated to have reduced by more than 50% for at least 4 wk. No change (NC) indicated the patient’s condition had no obvious change for at least 4 wk, the tumor size has increased less than 25% and decreased less than 50%. PD (worsen) indicated new lesions having appeared or lesions had increased by more than 25%.

**Zubrod-ECOG-WHO score:** 0 score stood for normal activities; 1 score stood for mild symptoms and almost normal activities; 2 score stood for the time staying in bed as less than 50% of the daytime; 3 score stood for the time staying in bed as more than 50% of the daytime; 4 score stood for completely bedridden; 5 score stood for death. Total efficiency = (CR + PR)/total number of cases × 100%.

**Statistical analysis**

SPSS16.0 software was used for statistical analysis. Continuous variables are expressed as a mean and standard deviation; the mean differences between the groups were compared by independent t-test and ANOVA, and χ² test was used to compare classified variables. Two values of data used two distribution tests. P < 0.05 indicated that the difference was statistically significant. Charts and tables were made by Prism GraphPad 4 software.

**RESULTS**

**Analysis of research subjects’ number**

All of the 100 patients completed the study.

**Results of whole blood test**

**Treatment group:** There was a transient decline of WBC and PLT within 12 h after treatment and by 3 d the lowest level was reached; the recovery rate decreased after 7 d, and the trend became stable after 21 d until the end of observation. This trend was relatively significant for WBC.

**Control group:** The whole blood cells declined on 3 d after radiotherapy, decreased significantly after 7 d, and reached the lowest point on 14 d. The degree of decrease was related to the radiation dose and tumor size. The difference between the treatment group and the control
group was statistically significant (Table 1 and Figure 1).

**Results of immunologic detection**

The aim was to observe the immune indexes, including CD4/8, CD45 and CD56.

**Treatment group:** There was a transient decline of CD4/CD8 within 12 h in the 150, 200 and 250 ng/kg subgroups. There was volatility rise between 3-14 d but the level remained below the pre-medication level, and went down after 21 d. There was a transient decline of CD45 and CD56 within 12 h, which rose after 3 d and went down after 21 d. The overall recovery improvement trend was obvious.

**Control group:** The trend of the immune indexes showed rebound on 3 d and a continuous downward trend after 7 d. There was no significant difference in these immune indexes between the other two groups (50 and 100 ng/kg subgroups) and the control group (Table 2 and Figure 2).

**Objective evaluation results**

The remission rate in the treatment group (84%) was obviously higher than that in the control group (60%), and the difference was statistically significant ($P < 0.05$). During the observation period, there were no recurrence, metastasis or death, and the survival time of patients was significantly prolonged. There were 2 patients in the 250 ng/kg subgroup that had low fever after administration, 1 in the 200 ng/kg subgroup and 2 in the 250 ng/kg subgroup that had mild impairment of liver function during the observation period. There was no other adverse event.

---

**Table 1 Results of whole blood test for the treatment group and the control group (mean ± SD, n = 10)**

<table>
<thead>
<tr>
<th>Group</th>
<th>Indicator</th>
<th>0 d</th>
<th>12 h</th>
<th>3 d</th>
<th>7 d</th>
<th>14 d</th>
<th>21 d</th>
<th>28 d</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>WBC (× 10^9/L)</td>
<td>7.66 ± 0.82</td>
<td>5.5 ± 0.67</td>
<td>4.2 ± 0.39</td>
<td>4.3 ± 0.48</td>
<td>4.21 ± 0.62</td>
<td>4.69 ± 0.38</td>
<td>4.89 ± 0.63</td>
</tr>
<tr>
<td></td>
<td>RBC (× 10^12/L)</td>
<td>3.92 ± 0.31</td>
<td>4.26 ± 0.43</td>
<td>3.9 ± 0.41</td>
<td>3.93 ± 0.22</td>
<td>4.38 ± 0.36</td>
<td>3.86 ± 0.34</td>
<td>3.89 ± 0.28</td>
</tr>
<tr>
<td></td>
<td>PLT (× 10^9/L)</td>
<td>358 ± 0.43</td>
<td>339 ± 31.45</td>
<td>232 ± 20.43</td>
<td>258 ± 19.2</td>
<td>275 ± 0.31</td>
<td>296 ± 0.29</td>
<td>321 ± 0.26</td>
</tr>
<tr>
<td>50 ng/kg</td>
<td>WBC (× 10^9/L)</td>
<td>6.13 ± 0.59</td>
<td>3.6 ± 0.35</td>
<td>4.27 ± 0.46</td>
<td>4.85 ± 0.35</td>
<td>4.52 ± 0.42</td>
<td>4.72 ± 0.39</td>
<td>5.18 ± 0.52</td>
</tr>
<tr>
<td></td>
<td>RBC (× 10^12/L)</td>
<td>5.43 ± 0.54</td>
<td>4.92 ± 0.53</td>
<td>4.16 ± 0.38</td>
<td>4.59 ± 0.82</td>
<td>4.73 ± 0.32</td>
<td>5.26 ± 0.37</td>
<td>5.63 ± 0.41</td>
</tr>
<tr>
<td></td>
<td>PLT (× 10^9/L)</td>
<td>231 ± 20.81</td>
<td>185 ± 18.24</td>
<td>195 ± 18.97</td>
<td>205 ± 1.8</td>
<td>226 ± 18.2</td>
<td>246 ± 17.5</td>
<td>229 ± 19.4</td>
</tr>
<tr>
<td>100 ng/kg</td>
<td>WBC (× 10^9/L)</td>
<td>8.4 ± 0.45</td>
<td>7.7 ± 7.89</td>
<td>5.3 ± 10.64</td>
<td>6.6 ± 9.83</td>
<td>6.1 ± 0.64</td>
<td>5.73 ± 0.47</td>
<td>5.9 ± 0.21</td>
</tr>
<tr>
<td></td>
<td>RBC (× 10^12/L)</td>
<td>6.3 ± 0.72</td>
<td>3.37 ± 0.43</td>
<td>3.2 ± 0.34</td>
<td>4.2 ± 0.37</td>
<td>4.78 ± 0.46</td>
<td>4.3 ± 0.42</td>
<td>4.6 ± 0.34</td>
</tr>
<tr>
<td></td>
<td>PLT (× 10^9/L)</td>
<td>3.4 ± 0.36</td>
<td>3.5 ± 0.37</td>
<td>3.2 ± 0.29</td>
<td>3.3 ± 0.28</td>
<td>3.6 ± 0.24</td>
<td>3.6 ± 0.26</td>
<td>3.4 ± 0.21</td>
</tr>
<tr>
<td>150 ng/kg</td>
<td>WBC (× 10^9/L)</td>
<td>2.8 ± 1.08</td>
<td>2.7 ± 1.26</td>
<td>1.9 ± 1.15</td>
<td>1.9 ± 1.12</td>
<td>2.0 ± 1.2</td>
<td>2.2 ± 1.3</td>
<td>2.6 ± 1.2</td>
</tr>
<tr>
<td></td>
<td>RBC (× 10^12/L)</td>
<td>3.6 ± 0.36</td>
<td>3.3 ± 0.2</td>
<td>3.1 ± 0.2</td>
<td>3.2 ± 0.3</td>
<td>3.4 ± 0.3</td>
<td>3.7 ± 0.2</td>
<td>4.1 ± 0.3</td>
</tr>
<tr>
<td></td>
<td>PLT (× 10^9/L)</td>
<td>384 ± 0.35</td>
<td>335 ± 21</td>
<td>292 ± 17.1</td>
<td>358 ± 17.2</td>
<td>332 ± 17.1</td>
<td>358 ± 17.2</td>
<td>384 ± 17.1</td>
</tr>
<tr>
<td>200 ng/kg</td>
<td>WBC (× 10^9/L)</td>
<td>5.3 ± 0.8</td>
<td>4.2 ± 0.3</td>
<td>3.2 ± 0.1</td>
<td>3.5 ± 0.32</td>
<td>3.6 ± 0.27</td>
<td>4.3 ± 0.31</td>
<td>5.4 ± 0.43</td>
</tr>
<tr>
<td></td>
<td>RBC (× 10^12/L)</td>
<td>4.6 ± 0.51</td>
<td>4.2 ± 0.41</td>
<td>4.1 ± 0.45</td>
<td>4.2 ± 0.37</td>
<td>4 ± 0.2</td>
<td>4.12 ± 0.34</td>
<td>4.5 ± 0.42</td>
</tr>
<tr>
<td></td>
<td>PLT (× 10^9/L)</td>
<td>278 ± 36</td>
<td>183 ± 19</td>
<td>149 ± 14</td>
<td>208 ± 22</td>
<td>259 ± 24</td>
<td>267 ± 25</td>
<td>271 ± 21</td>
</tr>
<tr>
<td>250 ng/kg</td>
<td>WBC (× 10^9/L)</td>
<td>3.6 ± 0.1</td>
<td>3 ± 0.37</td>
<td>2.7 ± 0.24</td>
<td>3.4 ± 0.4</td>
<td>4.2 ± 0.3</td>
<td>4.5 ± 0.4</td>
<td>4.2 ± 0.01</td>
</tr>
<tr>
<td></td>
<td>RBC (× 10^12/L)</td>
<td>3.6 ± 0.3</td>
<td>3.3 ± 0.2</td>
<td>3.1 ± 0.2</td>
<td>3.2 ± 0.3</td>
<td>3.4 ± 0.3</td>
<td>3.7 ± 0.2</td>
<td>4.1 ± 0.3</td>
</tr>
<tr>
<td></td>
<td>PLT (× 10^9/L)</td>
<td>364 ± 35</td>
<td>235 ± 21</td>
<td>240 ± 20</td>
<td>276 ± 22</td>
<td>342 ± 21</td>
<td>312 ± 20</td>
<td>312 ± 20</td>
</tr>
</tbody>
</table>

WBC: White blood cell; RBC: Red blood cell; PLT: Platelet.
found (Table 3).

ECOG score results
The aim was to observe the ECOG score for a period of a month after rhIL-12 intervention.

Treatment group: There were 26 patients (52%) with normal activities after treatment, and the difference was statistically significant as compared with the 10 cases (20%) before treatment ($P < 0.05$). The life quality of patients was significantly improved.

Control group: There were 20 patients (40%) with normal activities after treatment, and the difference was not statistically significant as compared with the 12 cases (24%) before treatment ($P > 0.05$) (Table 4).

Imaging evaluation results
There were two CT pictures, including 1 case of pancreatic cancer and 1 case of lung cancer in the treatment group, before and after treatment. The results showed that the original lesion was significantly reduced after treatment and no new lesions appeared (Figures 3 and 4).

Figure 1  Count changes of the whole blood test. A: Control group; B: 50 ng/kg subgroup; C: 100 ng/kg subgroup; D: 150 ng/kg subgroup; E: 200 ng/kg subgroup; F: 250 ng/kg subgroup. WBC: White blood cell; RBC: Red blood cell; PLT: Platelet.
DISCUSSION

The incidence of cancer is rising, and cancer has become one of the main causes of death\(^6\). In recent years, radiotherapy of malignant tumors has developed rapidly, especially for accurate radiotherapy. However, the clinical curative effect for patients who have larger or more numerous tumor lesions are often reduced due to adverse reactions after radiotherapy, such as immune injury and myelosuppression. Under normal circumstances, the immune systems maintain the physiological balance and stabilization of the body.

Immune cells are the first line of the anti-tumor system. Immune regulatory factors or cytokines participate in immune regulation by means of signal transduction\(^7\). Studies have shown that tumor cells can escape immunosurveillance through a number of special mechanisms. The immune system is critical to the body’s surveillance against cancer.

The immune function of about 86% of patients has been shown to be on the decline in the early stage of cancer, and to further decline after treatment, which is
and allergic reactions limit its clinical application and chills and fever, nausea and vomiting, pulmonary edema tumor blood vessels, but the adverse reactions such as adjust the immune function and inhibit the production of have found its abilities to improve immunity capability, at the stage of basic study and animal study. Many studies covered, and a large amount of the related research is still and inhibiting their growth reducing and blocking the nutrition source of tumor cells can prevent the formation of tumor blood vessels, thereby formation of interferon-inducible protein-10 (IP-10). IP-10 the ability to kill target cells. IL-12 also can promote the immunity, and it can induce the differentiation of T helper cell 1 (Th1), as well as promote the proliferation of NK cells and mononuclear cells, keratinocytes and dendritic cells. IL-12 mainly functions to mediate cellular macrophages, B cells, mononuclear cells, keratinocytes and dendritic cells. IL-12 mainly functions to mediate cellular immunity, and it can induce the differentiation of T helper cell 1 (Th1), as well as promote the proliferation of NK cells and T cells, further stimulate IFN-γ secretion, and enhance the ability to kill target cells. IL-12 also can promote the formation of interferon-inducible protein-10 (IP-10). IP-10 can prevent the formation of tumor blood vessels, thereby reducing and blocking the nutrition source of tumor cells and inhibiting their growth. It has been nearly 30 years since IL-12 was discovered, and a large amount of the related research is still at the stage of basic study and animal study. Many studies have found its abilities to improve immunity capability, adjust the immune function and inhibit the production of tumor blood vessels, but the adverse reactions such as chills and fever; nausea and vomiting, pulmonary edema and allergic reactions limit its clinical application and temper its promotion.

RhIL-12 is a new kind of biological agent secreted by Chinese hamster ovary cells through gene engineering. Its biological activity is similar to that of IL-12. The advantage of rhIL-12, however, is its high purity (> 98%), high activity (≥ 10000 IU/μg), low therapeutic dose and dosage that can be tolerated. Preliminary experimental study found that rhIL-12 is currently the only biological agent with the advantage of comprehensive recovery of hematopoietic function, regulation of the body’s immunity, inhibition of tumor angiogenesis and inhibition of tumor growth, thereby improving the life quality of patients with cancer. As an immune regulatory factor, it plays an important role in both primary and secondary immunity. Especially for radiotherapy patients who present with larger or more numerous tumor targets (more than two), it has important research value.

In our study, there were 100 patients who had larger or more numerous tumor s (more than two) and who received precision radiotherapy (Cyber knife or IGRT). The following conclusions are drawn. In the treatment group, the whole blood cells showed a transient decline within 12 h after treatment. The reason for this may be that the cell changes into the microcirculation or the bone marrow microenvironment, which may affect the proliferation of hematopoietic stem cells. The whole blood cells reached the lowest level at 3 d. People have always stopped treatment at this time, which represents a misunderstanding of the early research. The recovery rate decreased after 7 d, and the trend became stable after 21 d until the end of observation. This trend is relatively significant for WBC. Compared with the control group, the difference was significant, which indicated that the rhIL-12 was effective.

Observation of the immune indexes, including CD4/8, CD45 and CD56, showed a transient decline of CD4/CD8 within 12 h in the 150, 200 and 250 ng/kg subgroups in the treatment group, with volatile rises between 3-14 d, but remaining below the pre-medication level, and then decreasing after 21 d. There was a transient decline of CD45 and CD56 within 12 h, which rose up after 3 d and went down after 21 d. Compared with the control group, the difference was significant. The improvement tendency was obvious, which suggested that rhIL-12 could promote the immune function of the patients after radiotherapy.

From our observations of the clinical manifestations, 2 patients in the 250 ng/kg subgroup showed low fever after administration, which could be returned to normal after physical cooling. One patient in the 200 ng/kg subgroup and 2 in the 250 ng/kg subgroup showed mild injury of

<table>
<thead>
<tr>
<th>Table 3 Results of objective evaluation for the treatment group and the control group</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Group</strong></td>
</tr>
<tr>
<td>Treatment</td>
</tr>
<tr>
<td>Control</td>
</tr>
</tbody>
</table>

Compared with the control group, *P < 0.05. CR: Complete remission; PR: Partial remission.

<table>
<thead>
<tr>
<th>Table 4 Comparison of ECOG scores before and 1 mo after intervention for the treatment and control groups</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ECOG scores before treatment after treatment</strong></td>
</tr>
<tr>
<td><strong>Treatment group (n = 50)</strong></td>
</tr>
<tr>
<td>0</td>
</tr>
<tr>
<td>1</td>
</tr>
<tr>
<td>2</td>
</tr>
<tr>
<td>3</td>
</tr>
<tr>
<td>4</td>
</tr>
<tr>
<td><strong>Control group (n = 50)</strong></td>
</tr>
<tr>
<td>0</td>
</tr>
<tr>
<td>1</td>
</tr>
<tr>
<td>2</td>
</tr>
<tr>
<td>3</td>
</tr>
<tr>
<td>4</td>
</tr>
</tbody>
</table>

There was significant difference between the two groups, *P < 0.05.
liver function during the observation period, which could be returned to normal after liver-protecting therapy. The injury related to radiation or rhIL-12 needs to be further studied.

In addition, this study explored the relationship between biological activity and concentration. The result showed that there was no statistical difference among the 50 ng/kg subgroup, the 100 ng/kg subgroup and the control group for immune response. What’s more, the adverse reactions were mainly concentrated in the 200 and 250 ng/kg subgroups, which suggests that the suitable clinical dosage concentration in our study is 150 ng/kg. The anti-tumor activity of rhIL-12 has been shown in clinical trials, but its toxicity to some extent

Figure 3  Changes of computed tomography slice before and after treatment in pancreatic cancer patients. A: Pancreatic head tumor mass (4.4 cm × 3.6 cm × 5.3 cm) accompanied by dilation of intrahepatic and extrahepatic bile duct, pancreatic duct and gallbladder before treatment; B: Most of the pancreatic head mass disappeared in 2 mo after B treatment. Low obstruction disappeared.

Figure 4  Changes of computed tomography slice before and after treatment in lung cancer patients. A: Right peripheral lung tumor mass (4.5 cm × 4.8 cm × 4.0 cm) located in the right upper lobe of the right lung before treatment; B: The mass disappeared 1 year after treatment.
limits the application. Therefore, rhIL-12 still needs to be further researched.

In conclusion, rhIL-12 can prevent radiation damage, improve hematopoietic function, regulate immunity, reduce the side effect of radiotherapy and improve the quality of life of patients. It has good clinical application value and good development prospect as tumor auxiliary treatment.

**COMMENTS**

**Background**

Interleukin-12 (IL-12) is an immunoregulatory protein produced by macrophages, B cells, mononuclear cells, keratinocytes and dendritic cells, and its target point lies in early undifferentiated pluripotent hematopoietic stem cells. However, the adverse events related to IL-12, including fever, chills, decrease of peripheral blood cells and organ dysfunction, have limited its clinical application. Recombinant human interleukin-12 (rhIL-12) is an immunoregulatory protein produced by gene engineering technology. RhIL-12 has similar biological activity to IL-12, but with the advantage of high purity (> 98%), high activity and low therapeutic dose. RhIL-12 has become the only available agent which can not only restore hematopoietic function but also improve immune function. Basic experimental studies have found that the recovery of hematopoietic function after radiotherapy is helpful to avoid the rapid increase of single blood cells, which can lead to high fever, conjunctival hemorrhage, abnormal immune response, embolism and other detrimental side effects. But a large number of studies are basic in nature and based on animal experiments. The aim of the study was to explore the interventional effects of rhIL-12 on tumor patients receiving radiotherapy, including the complications after radiotherapy, the curative effects on hematopoietic function and immune function as well as dose-effect relationship, and to provide scientific basis for drug development and clinical application.

**Research frontiers**

Some studies have shown that rhIL-12 can stimulate various kinds of cytokines through stimulating the bone marrow microenvironment, either directly or indirectly, further promoting long-term hematopoietic reconstitution progenitor cells' differentiation and maturation, and instigate short-term hematopoietic reconstitution progenitor cells. These help to achieve a comprehensive recovery of hematopoietic function. In addition, in the circumstances of no supportive treatments, primate experiments demonstrated that using a low dose of rhIL-12 within 24 h after lethal dose irradiation could significantly improve (4-times) the animal's survival rate. What's more, rhIL-12 could promote the healing of skin wounds after radiation injury. As a radiation injury prevention drug, rhIL-12 is still effective at 24 h to 48 h after radiation. At the same time, a large number of animal experiments have shown that IL-12 can significantly inhibit the growth and metastasis of malignant tumors, prolonging the survival time of tumor-bearing animals. IL-12 can enhance the natural killer (NK) cell and cytotoxic T lymphocyte (CTL) cell response and the ability to induce production of IFN-γ, which indicates that it may have anti-tumor activity. IL-12 enhances the binding ability of NK cells and K562 target cells and tumor cell monolayer, and enhances the cytotoxicity of NK cells to tumor cells. Because rhIL-12 and IL-12 have similar biological activities, some studies have shown that low dose of rhIL-12 can inhibit tumor cell growth, and rhIL-12 has synergistic anti-cancer effect on radiotherapy and chemotherapy, which needs further clinical validation.

**Innovations and breakthroughs**

The study found that low-dose rhIL-12 has the effect of prevention and treatment for the decrease of blood cells after radiotherapy, and could effectively improve the immune function and reduce the complications of radiotherapy.

**Applications**

RhIL-12 can prevent radiation damage, improve hematopoietic function, regulate immunity, reduce the detrimental side effects of radiotherapy and improve the quality of life of patients.

**Terminology**

IL-12: Interleukin-12 is an immunoregulatory protein produced by macrophages, B cells, mononuclear cells, keratinocytes and dendritic cells, and its target point lies in early undifferentiated pluripotent hematopoietic stem cells; RhIL-12: Recombinant human interleukin-12 is an immunoregulatory protein produced by gene engineering technology; its biological activity is similar to IL-12.

**Peer-review**

The authors conducted an interesting clinical study on rhIL-12 for the prevention and treatment of complications after radiotherapy in patients with malignant tumors. The manuscript was well written. The methodology was clear and accurate. The results section was adequate.

**REFERENCES**


12. Robertson MJ, Soiffer RJ, Wolf SF, Manley TJ, Donahue C, Young D, Herrmann SH, Ritz J. Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and...


P- Reviewer: Liu G, Ozyigit G, Xiao EH S- Editor: Ji FF L- Editor: A E- Editor: Lu YJ